Integrated clinical and genetic prognostic models with or without cytogenetic information provide an additional way to stratify risk for transplantation-age patients with primary myelofibrosis (PMF) and assimilate prognostically relevant clinical, cytogenetic, and mutation data, researchers concluded after conducting a study involving >800 individuals. Participants were ≤70 years of age and had PMF. Investigators looked at variables that predicted overall survival, and developed prognostic models both with and without cytogenic information. Among the results:
- Hemoglobin <100 g/L, leukocytes >25 × 109/L, platelets <100 × 109/L, circulating blasts ≥2%, bone marrow fibrosis grade ≥2, constitutional symptoms, absence of CALR type-1 mutation, presence of high-molecular risk mutation, and presence of ≥2 or more high-molecular risk mutations negatively impacted overall survival.
- The model without cytogenic information revealed low-, intermediate-, and high-risk categories; overall survival rates were 95%, 70%, and 29%, respectively.
- The model with cytogenic information revealed low-, intermediate-, high, and very-high risk categories; overall survival rates were 91%, 66%, 42%, and 7%, respectively.
- Both models remained effective after including older patients.
Gugliemelli P, Lasho T, Rotunno G, et al. MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. [Published online ahead of print December 9, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.76.4886.
This Week's Must Reads
Limited Coverage of HCV Testing in US Since 2013, Clin Infect Dis; ePub 2018 Sep 15; Patel, et al
Smoking Status & Pain in Veterans with HCV, Pain Med; ePub 2018 Sep 7; Lynch, et al
Assessing the HCV Care Cascade in Baby Boomers, Am J Manag Care; 2018 Sep; Brady, Vellozzi, et al
HCV Screening in Elective Cranial Neurosurgery, J Neurosurg; 2018 Sep; Nussbaum, Kallmes, et al
Young Adults Who Inject Drugs & Risk of HCV, Health Promot Pract; ePub 2018 Sep 18; Knight, et al
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al